Long-Acting Buprenorphine Medications as a Novel Pharmacological Option in Opioid Dependence

被引：1

作者：

Soyka, Michael ^{[1
,2
]}

机构：

[1] Med Pk Chiemseeblick, Rasthausstr 25, D-83233 Bernau Felden, Germany

[2] Psychiat Univ Klin LMU Munchen, Munich, Germany

来源：

SUCHTTHERAPIE | 2020年 / 21卷 / 01期

关键词：

opioid dependence; maintenance treatment; buprenorphine; depot; implant; SUSTAINED-RELEASE FORMULATION; FOLLOW-UP; METHADONE-MAINTENANCE; USE DISORDER; HEROIN; ADDICTION; RETENTION; MORTALITY; BLOCKADE; RBP-6000;

D O I：

10.1055/a-1064-6188

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Opioid maintenance treatment with oral methadone or sublingual buprenorphine is an established first-line treatment in opioid dependence. Both drugs must be taken daily (methadone) or at least every second day (buprenorphine). Apart from the novel subcutaneous weekly and monthly depot formulations CAM 2038 (Buvidal (R)) 2 other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade (TM)) and a 6-month buprenorphine implant (Probuphine (TM)). Clininical findings of these three medications are given and possible clinical indications are discussed.

引用

页码：13 / 18

页数：6

共 50 条

[41] Inpatient initiation of long-acting injectable buprenorphine at a community hospital: A retrospective case series
O'Conor, Clarissa
Farhi, Shai
Cowan, Ethan
Fitzgerald, Ruchi
JOURNAL OF ADDICTIVE DISEASES, 2024,
[42] Prescription of Long-Acting Injectable Antipsychotic Medications Among Outpatient Mental Health Care Service Providers
Bunting, Samuel R.
Chalmers, Kristen
Lee, Royce
Yohanna, Daniel
PSYCHIATRIC SERVICES, 2023, 74 (11) : 1146 - 1153
[43] Opioid Use and Chronic Infections: The Value of Addressing the Syndemic in Correctional Settings Via Telemedicine Guidance and Broader Use of Long-Acting Medications
Krsak, Martin
Montague, Brian T.
Trowbridge, Paul
Johnson, Steven C.
Binswanger, Ingrid A.
JOURNAL OF INFECTIOUS DISEASES, 2020, 222 : S486 - S493
[44] Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study
Wiese, Andrew D.
Griffin, Marie R.
Schaffner, William
Stein, C. Michael
Greevy, Robert A.
Mitchel, Edward F., Jr.
Grijalva, Carlos G.
CLINICAL INFECTIOUS DISEASES, 2019, 68 (11) : 1862 - 1869
[45] Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
Citrome, Leslie
Belcher, Emily
Stacy, Sylvie
Suett, Mark
Mychaskiw, Marko
Salinas, Gregory D.
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 111 - 123
[46] Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
Kane, John M.
McEvoy, Joseph P.
Correll, Christoph U.
Llorca, Pierre-Michel
CNS DRUGS, 2021, 35 (11) : 1189 - 1205
[47] Direct induction onto high-dose long-acting injectable buprenorphine: A case series
Naren, Thileepan
Cook, Jon
Maccartney, Paul
AUSTRALASIAN PSYCHIATRY, 2024, 32 (03) : 238 - 241
[48] Comparative Pharmacokinetics and Injection Site Histopathology in Nude Mice Treated with Long-acting Buprenorphine Formulations
Illario, Jacqueline A.
Osborn, Kent G.
Garcia, Arnold, V
Sepulveda, Yadira J.
Momper, Jeremiah D.
Kiel, Jeffrey W.
Kirihennedige, Ayuri S.
Sun, Steven A.
Richter, Philip J.
JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE, 2023, 62 (02): : 147 - 152
[49] Comparison of the characteristics of patients treated with sublingual vs. long-acting injectable buprenorphine formulations for treatment of opioid use disorder: A retrospective cohort study
Nayer, Carmen
Sveticic, Jerneja
Abeysundera, Hesitha
Bui, Tuan Anh
AUSTRALASIAN PSYCHIATRY, 2022, 30 (06) : 754 - 758
[50] Significantly improved outcomes - both in retention and CGI scores - using Long Acting Buprenorphine (LAB-Buvidal) versus treatment as usual for Opioid Dependence in Wales during the Pandemic
Melichar, J.
Pearson, L.
Richards, E.
Lindsay, A.
Greenwood, R.
EUROPEAN PSYCHIATRY, 2022, 65 : S814 - S814

← 1 2 3 4 5 →